Similar Items: Independent prognostic value of peak width of skeletonized mean diffusivity on clinical progression in Alzheimer's disease
- Simulation of long‐term lecanemab treatment effect on Alzheimer's disease progression
- Polypharmacy is associated with lower progression from MCI to Alzheimer's disease, with sex‐specific patterns across drug classes
- CSF Biomarkers of Alzheimer’s Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design
- Heterogeneous trajectories of executive function in clinical Alzheimer's disease: Results from the 3C study
- Alzheimer's disease drug development pipeline: 2026
- Single‐subject proteomic signatures in Alzheimer's disease reflect clinical phenotypes and distinguish asymptomatic from symptomatic cases